Targeting Beta Cell Dysfunction With Liraglutide or Golimumab in Longstanding T1D

Phase 0 Completed 16 enrolled Carla Greenbaum, MD Juvenile Diabetes Research Foundation · collab

Non-randomizedSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to determine whether 8 weeks of Liraglutide or Golimumab can transiently improve beta cell function in patients with longstanding Type 1 diabetes (T1D) who secrete proinsulin and little/no C-peptide.

Timeline

Start: 2018-08-15
Primary completion: 2021-11-09
Completion: 2021-11-09

Outcome

Missed primary endpoint

paper At the completion of therapy, none of the individuals achieved the primary outcome of MMTT-stimulated C-peptide ≥ 0.02 ng/mL. PMID 38096190 ↗

Publications

Lord SM, Bahnson HT, Greenbaum CJ, Liljenquist DR, Virostko J, Speake C. Testing a new platform to screen disease-modifying therapy in type 1 diabetes. PLoS One. 2023 Dec 14;18(12):e0293268. doi: 10.1371/journal.pone.0293268. eCollection 2023.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Golimumab	Monoclonal antibody	—	Subcutaneous
Subject	Liraglutide	Peptide	—	Subcutaneous